tempusai

2,237 views
8 Discussing
加密王_
·
--
🤖 xTEM: AI IS TRANSFORMING HEALTHCARE! Tempus AI is bringing artificial intelligence and advanced data analytics into modern healthcare. Its focus on precision medicine and clinical intelligence puts it in an exciting technology sector. Healthcare innovation offers significant potential, while competition, regulation, and profitability remain important challenges. Watch $TEM ! #xTEM #tempusai #artificialintelligence #USDTfree
🤖 xTEM: AI IS TRANSFORMING HEALTHCARE!

Tempus AI is bringing artificial intelligence and advanced data analytics into modern healthcare. Its focus on precision medicine and clinical intelligence puts it in an exciting technology sector. Healthcare innovation offers significant potential, while competition, regulation, and profitability remain important challenges. Watch $TEM !

#xTEM #tempusai #artificialintelligence #USDTfree
·
--
Bullish
$TEM pre-market trades at 78.86 (+10.71%) as Tempus AI reports a strong Q3 earnings beat with $411.5M revenue (+23% YoY) and raises FY26 guidance. Momentum gained further boost from its multi-year strategic collaboration with Moderna and Merck. Daily RSI(6) sits at 70.17 after hitting a 24h high of 83.63. Defending the 75 support could setup another test of 83+ resistance. Are you trading this earnings momentum? ​#TEM #TempusAI #USMidtermElections
$TEM pre-market trades at 78.86 (+10.71%) as Tempus AI reports a strong Q3 earnings beat with $411.5M revenue (+23% YoY) and raises FY26 guidance. Momentum gained further boost from its multi-year strategic collaboration with Moderna and Merck. Daily RSI(6) sits at 70.17 after hitting a 24h high of 83.63. Defending the 75 support could setup another test of 83+ resistance.

Are you trading this earnings momentum?

​#TEM #TempusAI #USMidtermElections
🚨 TEMPEST IN AI HEALTHCARE? $TEM SURGES 36% IN 5 DAYS! Tempus AI ($TEM ) has jumped roughly 36% over five trading sessions, putting AI-powered healthcare back in the spotlight. 🔥 What’s driving the move? • 💰 Management highlighted potential future revenue from Medicare reimbursement changes • 🧬 Up to $80M–$100M potential revenue from its tissue-scanning test • 🩸 Potential $250M–$300M from liquid biopsy if the anticipated approval arrives • 📊 Q2 revenue reached $382.5M, up 22% YoY • 🤖 Tempus continues expanding AI-driven diagnostics, data licensing and precision medicine But after such a sharp move, momentum and valuation risk are worth watching. 👀 The bigger question: Can Tempus turn AI healthcare growth into sustained revenue and profitability? $TEM on your watchlist? Bullish 📈 or waiting for a pullback? 👇 {future}(TEMUSDT) #TempusAI #TEM #AI #Healthcare #StockMarket
🚨 TEMPEST IN AI HEALTHCARE? $TEM SURGES 36% IN 5 DAYS!

Tempus AI ($TEM ) has jumped roughly 36% over five trading sessions, putting AI-powered healthcare back in the spotlight.

🔥 What’s driving the move?

• 💰 Management highlighted potential future revenue from Medicare reimbursement changes
• 🧬 Up to $80M–$100M potential revenue from its tissue-scanning test
• 🩸 Potential $250M–$300M from liquid biopsy if the anticipated approval arrives
• 📊 Q2 revenue reached $382.5M, up 22% YoY
• 🤖 Tempus continues expanding AI-driven diagnostics, data licensing and precision medicine

But after such a sharp move, momentum and valuation risk are worth watching.

👀 The bigger question:
Can Tempus turn AI healthcare growth into sustained revenue and profitability?

$TEM on your watchlist?
Bullish 📈 or waiting for a pullback? 👇
#TempusAI #TEM #AI #Healthcare #StockMarket
Verified
$RXRX.US The AI biopharma wave has finally reached this small-cap stock~ Recursion recently extended its partnership with Tempus AI through 2029. Tempus also received a global, non-exclusive license to RXRX’s RNA foundation model, TxFM. The agreement includes $42 million in guaranteed payments over the next three years. This means RXRX’s AI drug-discovery platform is moving toward real-world commercial validation! The sector leader $TEM has been unusually strong lately and is now gearing up to challenge the heavy daily-chart resistance zone at 88–90 again! {future}(TEMUSDT) $MRNA will officially join the Nasdaq 100 on the 9th—that is, the day after tomorrow. It’s up nearly 600% this year! It has now returned to weekly-chart resistance at 208–220. With its own positive news and strength across the sector, it’s also reached the point where short-term gains could be taken, so don’t chase it~ {future}(MRNAUSDT) Meanwhile, RXRX bounced back from oversold territory yesterday, and the bulls finally stepped up to hit the shorts! It surged right up to the daily-chart resistance around $5–$5.20! Those of you who bought this U.S. stock lottery ticket at $3–$3.30 can breathe easy again—you’ve made enough for a week’s worth of breakfasts! 😂 Be content and happy~ #Ai生物制药 #tempusai {stock_us}(RXRX.US)
$RXRX.US

The AI biopharma wave has finally reached this small-cap stock~

Recursion recently extended its partnership with Tempus AI through 2029. Tempus also received a global, non-exclusive license to RXRX’s RNA foundation model, TxFM. The agreement includes $42 million in guaranteed payments over the next three years.

This means RXRX’s AI drug-discovery platform is moving toward real-world commercial validation!

The sector leader $TEM has been unusually strong lately and is now gearing up to challenge the heavy daily-chart resistance zone at 88–90 again!
$MRNA will officially join the Nasdaq 100 on the 9th—that is, the day after tomorrow. It’s up nearly 600% this year! It has now returned to weekly-chart resistance at 208–220. With its own positive news and strength across the sector, it’s also reached the point where short-term gains could be taken, so don’t chase it~

Meanwhile, RXRX bounced back from oversold territory yesterday, and the bulls finally stepped up to hit the shorts! It surged right up to the daily-chart resistance around $5–$5.20!

Those of you who bought this U.S. stock lottery ticket at $3–$3.30 can breathe easy again—you’ve made enough for a week’s worth of breakfasts! 😂
Be content and happy~

#Ai生物制药 #tempusai
RXRXUS-4.80%
MRNA+0.25%
TEM-0.01%
🤖 xTEM: WHERE ARTIFICIAL INTELLIGENCE MEETS THE FUTURE OF MEDICINE! Artificial intelligence is transforming industries, but one of its most meaningful opportunities could be healthcare. Tempus AI ($TEM ) is developing technology that combines artificial intelligence, clinical data, and advanced diagnostics to support more personalized approaches to medicine. Its business operates at the intersection of healthcare innovation, precision medicine, oncology diagnostics, and data analytics. Tempus delivered impressive Q3 2026 results. Revenue increased 23% year over year to $411.5 million. Its Data and Applications segment grew 33%, while oncology testing volume increased 32%. The company also raised its 2026 revenue guidance to approximately $1.60–$1.605 billion. These developments strengthen the growth narrative, but investors should not ignore the risks. Profitability, competition, healthcare regulations, data privacy, and the costs of expanding AI infrastructure remain important factors. The powerful opportunity: xTEM provides tokenized exposure to a company working to connect healthcare intelligence with artificial intelligence. The next generation of medicine may be increasingly data-driven. Tempus is positioning itself in that transformation, but execution will determine how much long-term value it creates. #xTEM #TempusAI #artificialintelligence: #HealthcareTechnology #USDTfree
🤖 xTEM: WHERE ARTIFICIAL INTELLIGENCE MEETS THE FUTURE OF MEDICINE!

Artificial intelligence is transforming industries, but one of its most meaningful opportunities could be healthcare.

Tempus AI ($TEM ) is developing technology that combines artificial intelligence, clinical data, and advanced diagnostics to support more personalized approaches to medicine.

Its business operates at the intersection of healthcare innovation, precision medicine, oncology diagnostics, and data analytics.

Tempus delivered impressive Q3 2026 results. Revenue increased 23% year over year to $411.5 million. Its Data and Applications segment grew 33%, while oncology testing volume increased 32%.

The company also raised its 2026 revenue guidance to approximately $1.60–$1.605 billion.

These developments strengthen the growth narrative, but investors should not ignore the risks. Profitability, competition, healthcare regulations, data privacy, and the costs of expanding AI infrastructure remain important factors.

The powerful opportunity: xTEM provides tokenized exposure to a company working to connect healthcare intelligence with artificial intelligence.

The next generation of medicine may be increasingly data-driven. Tempus is positioning itself in that transformation, but execution will determine how much long-term value it creates.

#xTEM #TempusAI #artificialintelligence: #HealthcareTechnology #USDTfree
·
--
Bullish
At present, the most useful real-world application of AI is still healthcare + AI: collecting patient data and medication records, making diagnoses, conducting consultations, and gathering data for large-scale models to improve healthcare efficiency and protect people's health. #tempusai
At present, the most useful real-world application of AI is still healthcare + AI: collecting patient data and medication records, making diagnoses, conducting consultations, and gathering data for large-scale models to improve healthcare efficiency and protect people's health.
#tempusai
Log in to explore more content
Join global crypto users on Binance Square
⚡️ Get latest and useful information about crypto.
💬 Trusted by the world’s largest crypto exchange.
👍 Discover real insights from verified creators.
Email / Phone number